Perspective Therapeutics Inc Stock Price, News & Analysis

Perspective Therapeutics (NYSE AMERICAN: CATX) announced progress in its Phase 1/2a clinical trial for [212Pb]VMT01, a targeted alpha-particle therapy for metastatic melanoma. The company has dosed the first patient with a higher dose of 3.0 mCi in combination with Bristol Myers Squibb's nivolumab (Opdivo®).

The advancement follows the Safety Monitoring Committee's review of encouraging results from previous cohorts, including five patients treated with 1.5 mCi monotherapy and two patients receiving the combination therapy at 1.5 mCi. Additionally, the company has reopened enrollment for the 3.0 mCi monotherapy cohort.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, has appointed Joel Sendek as Chief Financial Officer, effective September 4, 2025. Sendek brings significant experience as a biotech CFO and Wall Street analyst, having previously served as CFO at Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma.

As CFO, Sendek has successfully raised over $2.5 billion in corporate transactions. His background includes leadership roles at Stifel, Lazard, and Oppenheimer, where he earned Wall Street Journal recognition as an All-Star Analyst with a #1 ranking in stock picking. He succeeds Juan Graham in the role.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, has appointed Maya Martinez-Davis as an independent director to its Board of Directors. Martinez-Davis currently serves as President of GSK's U.S. Commercial business and brings extensive experience in oncology and biopharma from previous executive roles at Merck KGaA and Pfizer.

The appointment strengthens Perspective's board as the company advances its three clinical-stage programs in the radiopharmaceutical field. Martinez-Davis's expertise in commercial and clinical development in oncology aligns with the company's focus on developing alpha-emitting radioisotope treatments for various cancers.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on advanced cancer treatments, has announced its participation in three major healthcare conferences in September 2025.

The company will participate in the Cantor Global Healthcare Conference on September 4 with a fireside chat, the Morgan Stanley Global Healthcare Conference on September 9, and the OPCO Targeted Radiopharmaceutical Therapies in Oncology Summit on September 11. At the OPCO summit, the company will participate in two panel discussions focusing on market competition and emerging therapeutic platforms.

Perspective Therapeutics (NYSE:CATX) reported Q2 2025 results and provided clinical updates on its radiopharmaceutical pipeline. The company's lead candidate [212Pb]VMT-α-NET showed promising results in neuroendocrine tumors, with 4 out of 7 patients in Cohort 2 experiencing objective responses and 7 of 9 patients remaining progression-free after one year. The FDA approved advancement to Cohort 3 (6.0 mCi) in June 2025.

The company reported $192M in cash as of June 30, 2025, expected to fund operations into late 2026. Q2 2025 financial results showed a net loss of $21.5M ($0.29 per share), compared to $11.7M in Q2 2024. R&D expenses increased 79% to $16.6M, while G&A expenses rose 40% to $7.7M.

Clinical progress continues across three programs: VMT-α-NET, VMT01 for melanoma, and PSV359 for FAP-α expressing tumors. Updated trial results will be presented at ESMO Congress 2025 in October.

Perspective Therapeutics (NYSE AMERICAN: CATX) announced that updated data from their [212Pb]VMT-α-NET program will be presented at the ESMO Congress 2025 in Berlin, Germany. The presentation, scheduled for October 20, 2025, will be delivered by Dr. Thorvardur Halfdanarson from Mayo Clinic Comprehensive Cancer Center.

The presentation will focus on safety and preliminary efficacy data from 44 patients in dose-finding cohorts 1 and 2. The study involves patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who haven't received prior RPT. Previous interim results were presented at ASCO 2025, and additional follow-up data from 33 patients enrolled after Cohort 2's reopening will be available.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on advanced cancer treatments, has scheduled its Q2 2025 financial results announcement for Wednesday, August 13, 2025, before market opening. The company will also provide business updates during this announcement.

The press release will be accessible through the newsroom section of Perspective's website.

Perspective Therapeutics (CATX) has advanced its Phase 1/2a clinical trial for [212Pb]VMT-α-NET by opening Cohort 3 after FDA alignment. The trial targets patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who haven't received prior radiopharmaceutical therapies. Cohort 3 will administer higher doses (6 mCi) - a 20% increase from Cohort 2. Patients weighing over 60kg will receive four fixed doses every eight weeks, while those under 60kg will receive 100μCi/kg. The company will evaluate dose-limiting toxicities in up to eight patients within 42 days of first treatment to determine maximum tolerated or feasible dose. Initial results from Cohort 2 showed promising anti-tumor activity with primarily low-grade adverse events. The company plans to present additional clinical updates, including safety follow-up and anti-tumor activities, at scientific conferences in the second half of 2025.

Perspective Therapeutics (NYSE: CATX) presented two key studies at SNMMI 2025 Annual Meeting in New Orleans. The first presentation focused on dosimetry findings for [212Pb]VMT-α-NET in treating neuroendocrine tumors, demonstrating feasibility and well-tolerated safety profile in Phase 1/2a trials. The study suggests this dosimetric approach could be valuable for developing 212Pb-based therapies. The second presentation introduced [68Ga]PSV377, a novel PET imaging agent for FAP-α expressing tumors, showing promising results in preclinical studies and first-in-human imaging, with superior tumor uptake compared to 18F-FDG in metastatic colorectal cancer patients.